Wellorithm vs Maximus: 50-State Access or Lower Monthly Price?

Quick verdict: Wellorithm vs Maximus

The primary difference in the Wellorithm vs Maximus comparison is access versus price. Wellorithm emphasizes licensed clinicians in all 50 states and offers both compounded semaglutide and tirzepatide, while Maximus highlights a low flat rate at $132.99 per month for compounded semaglutide. If you need broad state coverage or tirzepatide availability, Wellorithm is the clearer fit; if transparent low monthly pricing for semaglutide is your priority, Maximus is the simpler option.

Check Wellorithm eligibility and 2-minute quiz

How they differ: key comparison points

This article compares Wellorithm and Maximus side by side on the most distinctive differences supported by the source: geographic clinician coverage, pricing model and transparency, medication options, pharmacy sourcing and shipping, and platform positioning and guarantees. The primary keyword Wellorithm vs Maximus appears throughout to help searchers find this direct comparison.

1. Geographic clinician coverage and availability

Wellorithm: licensed clinicians in all 50 states, described as broader coverage than many smaller platforms. That is offered as a core strength for patients in states where other providers lack presence.

Maximus: available in all 50 states except Mississippi for its Weight Loss Protocol as captured on its landing page. The difference is explicit: Wellorithm claims full 50-state clinician coverage, while Maximus excludes Mississippi for that specific program.

2. Pricing model and transparency

Wellorithm: marketing shows “Only $147” start and multiple starting price lines, but the FAQ states Wellorithm does not publish pricing on its site and you receive a personalized quote after the intake quiz. That means pricing is presented in promotional lines yet final cost is quote-based.

Maximus: lists a clear direct-pay flat rate at $132.99 per month for semaglutide and positions that as a low, transparent monthly price. Its FAQ confirms the $132.99/month figure as published pricing.

3. Medication options: semaglutide and tirzepatide

Wellorithm: explicitly offers both compounded semaglutide and compounded tirzepatide across injection and oral dissolving tablet formats, with marketing lines listing multiple starting figures for different formulations. It also includes the regulatory qualifier that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Maximus: focuses on compounded semaglutide. Maximus has limited published detail on tirzepatide availability. Both platforms provide compounded medication rather than branded finished products, and both include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

4. Pharmacy sourcing, shipping and refunds

Wellorithm: advertises fully virtual consultations with medication shipped to your home and promotional lines such as fast, free shipping in landing-page copy. Specific pharmacy sourcing details beyond “compounded” are not published in the supplied evidence.

Maximus: indicates prescriptions are filled through trusted U.S. pharmacies and lists free priority or expedited shipping. Maximus also states if you are not approved for treatment your medication costs will be fully refunded. These are explicit claims in the source material.

5. Platform positioning and guarantees

Wellorithm: positions itself as a smaller national platform that fills access gaps, with a Weight Loss Guarantee and claims like “No membership or hidden fees” in landing-page captured copy, while noting fewer public reviews than larger competitors.

Maximus: positions itself as a simple, low-cost direct-pay option, with transparent monthly pricing and mentions of published study results for semaglutide in landing-page content. Maximus does not publish a weight-loss guarantee in the supplied evidence.

Comparison table: Wellorithm vs Maximus

See Maximus $132.99/month semaglutide plan

Deciding factors: which fits you

If geographic access or having both semaglutide and tirzepatide options matters, Wellorithm is framed as the better match because of its 50-state clinician coverage and explicit tirzepatide offerings. If simple, transparent low monthly pricing for compounded semaglutide is the priority, Maximus offers a published $132.99/month direct-pay model and domestic pharmacy fulfillment.

Start Wellorithm quiz to get a personalized quote

Check Maximus availability in your state

Final thoughts on Wellorithm vs Maximus

Wellorithm vs Maximus boils down to trade offs the sources list: Wellorithm offers national clinician coverage and multiple compounded GLP-1 options, though final pricing is provided after a quiz; Maximus publishes a low $132.99/month semaglutide rate with trusted U.S. pharmacy fulfillment but has less published detail on tirzepatide and excludes Mississippi for the cited program. Both use compounded medications that are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Use the guidance below to pick based only on the supplied facts.

Choose Wellorithm if you need licensed clinicians in all 50 states or want access to both compounded semaglutide and compounded tirzepatide and are comfortable receiving a personalized price quote after the intake quiz.

Choose Maximus if you want a simple, transparent direct-pay semaglutide plan with a published $132.99/month rate and prescriptions filled through trusted U.S. pharmacies.

Begin Wellorithm eligibility quiz now